Results 221 to 230 of about 398,508 (313)
Voclosporin‐induced gingival enlargement: A case report
Abstract Background Drug‐influenced gingival enlargement (DIGE) is a recognized adverse effect of certain medications, particularly immunosuppressants like cyclosporin and tacrolimus. However, there have been no documented cases of DIGE associated with voclosporin, a newer calcineurin inhibitor used primarily to treat lupus nephritis.
Francesca Racca +2 more
wiley +1 more source
Tenascin-C as a predictor of delayed graft function after kidney transplantation. [PDF]
Yan Z +8 more
europepmc +1 more source
ABSTRACT Background Advanced heart failure (HF) remains a clinical challenge, and mitral transcatheter edge‐to‐edge repair (M‐TEER) has emerged as a potential bridging strategy. Aims To describe the clinical outcomes of M‐TEER in a single‐center cohort of patients with advanced HF and to identify anatomical and clinical features potentially associated ...
Pedro Castilhos de Freitas Crivelaro +8 more
wiley +1 more source
WCN25-2419 COMPLEMENT COMPONENT 4d(C4d) DEPOSITION AND PROGNOSIS IN LUPUS NEPHRITIS
Riyadh Al-Saegh +5 more
doaj +1 more source
Enhancing Kidney Transplantation Outcomes Through Robotic-Assisted Paired Kidney Exchange: A Case Report. [PDF]
Turra V +6 more
europepmc +1 more source
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves +8 more
wiley +1 more source
Hypercalcemia in Patients After Kidney Transplantation. [PDF]
Miedziaszczyk M +8 more
europepmc +1 more source
Evaluating TikTok and YouTube as patient-education resources on kidney transplantation: a comparative analysis. [PDF]
Ding R +8 more
europepmc +1 more source
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra +4 more
wiley +1 more source

